Hims & Hers announced a distribution partnership with Novo Nordisk on March 9, 2026, simultaneously announcing that it will sunset its compounded semaglutide and tirzepatide programs for new patients. Existing patients on compounded regimens will be transitioned to brand-name product where insurance allows, or offered a continuation pathway through Hims's prior compounding partners.
The move is the most significant industry consolidation since FDA delisted semaglutide and tirzepatide from the Drug Shortages list. Hims's market scale and brand visibility had made it the largest direct-to-consumer compounded-GLP-1 channel; the pivot likely accelerates the broader market migration back toward brand-name product for patients with coverage, and toward smaller pure-play compounded telehealth programs for cash-pay patients.
Our 2026 ranking reflects this shift — Hims's score has been adjusted to reflect the announced transition pathway. We will publish a fuller re-review once the new operating model is in steady state.